Werfen, a global leader of in vitro diagnostics,keeps growing•

With a 13.2% increase in operating income, turnover has
increased by 5.3%, reaching 1.359 billion euros in 2018

•Werfen is a worldwide leader in the Hemostasis, Acute Care
Diagnostics, and Autoimmunity areas•

Under President Marc Rubiralta, Werfen ownership has confirmed
its long-term focus and commitment, which invested 93 million
euros in R&D in 2018•

Luis Cantarell has joined the Executive Board as an independent
board member

Barcelona, 25 April 2019. Werfen, a global leader in specialized products in the health andlife sciences sectors, has achieved a turnover of 1.359 billion euros in 2018, an increase of
5.3% from the previous year. With patients at the center of its activities, Werfen offers
innovative solutions to hospitals and clinical laboratories, aiming to improve healthcare byproviding maximum value.
Werfen continues to strengthen its in vitro diagnostics (IVD(1)) leadership position, with anabove market growth of 6.5%. Growth in North America stands out at 6.5%, followed closely
by the Asia-Pacific and Latin America regions at 6.2%. Accounting for 42% of the Werfen
workforce (including R&D and manufacturing), North America is one of the main and mostcompetitive markets, currently representing 26% of total sales. Likewise, Western Europe
continues to be the largest market, representing 42% of total sales. China, Latin America, andEEMEAI (Eastern Europe, the Middle East, Africa, and India) are the regions expected to show
the greatest future growth.
Consolidated net profit reached 161 million euros, slightly outpacing the previous year, while
EBITDA exceeded 301 million euros, a 6% increase compared to 2017. In addition, operating
income grew by 13.2% to 205 million euros.
The corporation’s main areas of expertise show excellent evolution, with overall growth
exceeding the state of the market. Hemostasis(2), the organization’s main business focus, roseby 4.7%. Acute Care Diagnostics(3) grew by 8.3% following the integration of portfolios fromrecent acquisitions. Autoimmunity(4) increased by 9.2%.
In 2018, the integration of Accriva Diagnostics (leader in point-of-care diagnostic tests(5) forhemostasis in operating theaters and intensive care units) and Tem (specialized in technology
assisting handling blood transfusions) were successfully completed (acquired in 2017 and2016 respectively). Therefore, the Acute Care Diagnostics business line has gained a broader
portfolio of products with comprehensive solutions for emergency, traumatology, operating
theaters units, as well as other hospital areas.

1Strengthening governance and commitment to R&D
Marc Rubiralta became president of Werfen in January this year and is determined to maintainthe Rubiralta Giralt family’s long-term focus and commitment to the organization. With this inmind, the Board has been reinforced by the arrival of Luis Cantarell serving as an independent
board member. Luis Cantarell will contribute his experience in global markets and various
areas of the healthcare sector.
With the firm belief that today's research and development (R&D) will bring about tomorrow’sprogress, Werfen invested 93 million euros in 2018.
Regarding future plans, President Marc Rubiralta says "at Werfen, we put patients at thecenter of everything we do to offer greater value to society as a whole. That’s why we remaincommitted to R&D, to steer us into the future." An example of this is the new Biokit
technological center in Barcelona which was completely relocated and is now operating at fullcapacity
The major Werfen R&D and production centers are located in Bedford (Massachusetts, USA),San Diego (California, USA), Orangeburg (New York, USA), Munich (Germany), andBarcelona (Spain).
New products in 2018 and priorities for 20192018 was a year full of new products aimed at improving the quality of information available tohealthcare professionals and enhancing the efficiency of the healthcare system. In China,
Werfen launched the ACL TOP® Family 50 Series, a hemostasis testing system detecting
preanalytical errors and, on a global scale, ProDx TM, a remote device monitoring system withpredictive capabilities. Acute Care Diagnostics business line launched, in the US and selectAsian and European markets, GEM® Premier™ 5000, to measure analytical parameters in
critical or chronic patients with metabolic and/or respiratory diseases. Furthermore,
VerifyNow® was released in Europe to assist in cardiovascular and neurological procedures.
As for autoimmunity, QUANTA-Lyser® 3000 was consolidated as a diagnosis system and theUS regulatory agency (Food and Drug Administration) approved the QUANTA Flash ® HMGCRmarker to aid in the diagnosis of idiopathic inflammatory myopathy, and the QUANTA Flash®
Calprotectin marker to assist in the diagnosis of gastrointestinal diseases, such as ulcerative
colitis and Crohn's disease.
All these innovations are reflected in the organization’s evolution. As stated by CEO Carlos
Pascual, "the trajectory at Werfen over recent years has been very positive and I am not only
referring to solid economic results. Our team of over 5,000 exceptionally talented andcommitted professionals, along with our focus on innovation and value, are what make thedifference." Considering these assets, Werfen is optimistic about its future.
The goals for 2019 are to further strengthen the main areas of expertise in Hemostasis, Acute
Care Diagnostics, and Autoimmunity, as well as to continue growing in China, and boost
expansion in the emerging markets of Latin America, Asia-Pacific and EEMEAI.

2Werfen
Werfen is one of the leading global companies in the IVD sector, specializing in the areas ofHemostasis and Acute Care Diagnostics through its company Instrumentation Laboratory, andin the area of Autoimmunity through its company Inova Diagnostics. Werfen also provides
manufacturing for third parties (reagents(6) and biomaterials(7)) and infectious disease serology
through its company Biokit, as well as clinical software and clinical chemistry. Over 1.5 million
samples are analyzed in laboratories around the world every day with Werfen reagents andsystems, to the benefit of patients.
In addition, Werfen manufactures medical devices through its company Leventon, which
specializes in infusion therapy(8). Werfen distributes medical devices and scientific instruments
through Izasa Hospital and Izasa Scientific in Spain and Portugal and through companies itowns in other European territories.
Werfen operates directly in nearly 30 countries and through distributors in over 100 territories.
For more information, please visit www.werfen.com(1)

In Vitro Diagnostics (IVD): Non-invasive tests performed on biological samples, usually blood, todiagnose, monitor, or rule out a disease.
(2)

Hemostasis: Hemostasis disorders occur when blood loses its usual liquidity and can result inhemorrhage or the formation of clots.
(3)

Acute Care Diagnostics: The specialized treatment of life-threatening conditions requiring rapid andcomprehensive medical attention and frequent monitoring, usually in intensive care units, emergency
rooms, and operating theaters.
(4)

Autoimmunity: Autoimmune diseases occur when the body's immune system fails to distinguishbetween normal body tissue and antigens, resulting in an immune response that destroys healthy tissues.
Autoimmune diseases include rheumatoid arthritis, lupus erythematosus, celiac disease, and Crohn’sdisease, among others.
(5)

Point-of-care testing (POCT): POCT is defined as medical tests at or near the point of patient care.

(6) Reagents: A substance or a compound added to a system to cause a chemical reaction.

Reagents

are often used to indicate the presence of another substance.
(7)

Biomaterials: Any substance of biological origin (usually proteins) that has been designed, produced,and purified to function as the main raw material on an IVD test.
(8)

Infusion Therapy: The administration of drugs directly into a vein through a needle or catheter.

Legal noticeThis document contains forward-looking statements about our business, financial data, and events related to theprospects of Werfen. These forecasts can be identified by the use of words such as “expectation”, “vision”,“anticipation”, “intention”, “plan”, “belief”, “search”, “estimate”, “future”, “project”, or words with a similar meaning. We
may also make projections in other reports, presentations, and press releases. Furthermore, our sales representativesmay occasionally make forward-looking statements. These projections are based on our current expectations and on
certain hypotheses, many of which are beyond the corporation’s control and subject to a series of risks anduncertainties. In the event that any of these risks or uncertainties should materialize or the underlying expectations
3

are not fulfilled, the results or performance of Werfen may differ substantially (either positively or negatively) fromthose explicitly or implicitly forecast. Werfen assumes no obligation to update or revise any forward-looking statements
made previously.

Press contact:
WerfenGloria Maltas
Corporate Image & Communication Manager
Telephone 93-401-01-01
gmaltas@werfen.com

Atrevia
Communication Agency
Alberto Valle
Telephone 93-419-06-30
avalle@atrevia.com

4•

Appendix 1 – Additional charts

Werfen Sales (million €)YearIVD

2018

2017

1,183

1,145

+6.5%

176

192

-2.2%

1,359

1,337

+5.3%

Medical Devices
Total Sales

Organic growth** In constant currency.

Financial Highlights (million €)2018

2017

VariationEBIT*

205

197

+4.1%

Net Profit

161

160

+0.8%

EBITDA**

301284+6.1%

Net Cash Position-165-264+37.5%

9393---R+D* Earnings before interest and taxes.
** Earnings before interest, tax, depreciation, and amortization

Sales Distribution by Region

5•Appendix 2 – Supporting images

Logo

Marc Rubiralta, Werfen President

Headquarters
Werfen Tower in L’Hospitalet de Llobregat, Barcelona

6New Biokit technological center in Lliçà d’Amunt, Barcelona

Fact Sheet
Company name: Werfen
Founded: 1966, Barcelona
Divisions:▪

IVD - Main areas of expertiseo Hemostasiso Acute Care Diagnostics
o Autoimmunity▪

Other areas of expertiseo OEM (Original Equipmentmanufacturing for third parties
o Infectious Disease Serology
o Clinical Softwareo Clinical Chemistry▪

Manufacturer).

Reagent

andbiomaterial

Medical devices
o Infusion Therapy
o Medical Device and Scientific Instrument Distribution

Sales in 2018: 1.359 billion euros, 5.3% increase compared to the previous year (1.337 billion
euros in 2017).
EBITDA 2018: 301 million euros (284 million euros in 2017).
Sales by region:
▪
▪
▪
▪
▪

Western Europe: 42% (3.7% increase compared to 2017)
North America: 26% (6.5% increase compared to 2017)
Asia-Pacific: 17% (6.2% increase compared to 2017)
EEMEAI: 8% (3.5% increase compared to 2017)
Latin America: 7% (6.2% increase compared to 2017)

R&D investment: 93 million euros (also 93 million euros in 2017).
Average workforce: 5,155 employees in nearly 30 countries.
Headquarters: Barcelona (Plaza de Europa, 21-23. 08908 L’Hospitalet de Llobregat).
Worldwide presence: Direct presence in nearly 30 countries and over 100 territories throughdistributors. Over 1.5 million samples are analyzed in laboratories around the world every daywith Werfen reagents and systems, to the benefit of patients.
R+D and production centers: Instrumentation Laboratory (Hemostasis and Acute Care
Diagnostics - USA and Germany), Inova Diagnostics (Autoimmunity - USA), Biokit (OEM - Spain)and Leventon (Infusion Therapy - Spain).
Main logistics centers: Devens (USA), Roncello (Italy), Hong Kong (China), Tarancón (Spain),and Cuautitlan Izcalli (Mexico).

7